Guangdong VTR Bio-Tech Co., Ltd. (300381.SZ)
CNY 8.04
(1.9%)
CNY 8.04
(1.9%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 796.02 Million CNY | -32.2% |
| 2022 | 1.17 Billion CNY | -37.95% |
| 2021 | 1.89 Billion CNY | -1.18% |
| 2020 | 1.91 Billion CNY | -6.51% |
| 2019 | 2.04 Billion CNY | 15.83% |
| 2018 | 1.76 Billion CNY | 17.94% |
| 2017 | 1.49 Billion CNY | -0.87% |
| 2016 | 1.51 Billion CNY | 115.0% |
| 2015 | 703.47 Million CNY | 95.51% |
| 2014 | 359.81 Million CNY | 0.18% |
| 2013 | 359.15 Million CNY | 6.44% |
| 2012 | 337.42 Million CNY | 24.76% |
| 2011 | 270.45 Million CNY | 24.71% |
| 2010 | 216.86 Million CNY | 20.57% |
| 2009 | 179.87 Million CNY | 22.16% |
| 2008 | 147.24 Million CNY | 71.83% |
| 2007 | 85.69 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 198.84 Million CNY | 2.17% |
| 2024 Q3 | 211.22 Million CNY | 6.47% |
| 2024 Q2 | 198.38 Million CNY | -0.23% |
| 2023 Q4 | 194.61 Million CNY | -11.11% |
| 2023 FY | 796.02 Million CNY | -32.2% |
| 2023 Q1 | 180.85 Million CNY | -17.5% |
| 2023 Q2 | 201.6 Million CNY | 11.47% |
| 2023 Q3 | 218.93 Million CNY | 8.6% |
| 2022 Q3 | 200.91 Million CNY | -39.18% |
| 2022 Q1 | 423.52 Million CNY | -29.84% |
| 2022 Q2 | 330.35 Million CNY | -22.0% |
| 2022 FY | 1.17 Billion CNY | -37.95% |
| 2022 Q4 | 219.21 Million CNY | 9.11% |
| 2021 Q1 | 397.41 Million CNY | -17.86% |
| 2021 Q2 | 473.72 Million CNY | 19.2% |
| 2021 Q3 | 417.37 Million CNY | -11.9% |
| 2021 Q4 | 603.63 Million CNY | 44.63% |
| 2021 FY | 1.89 Billion CNY | -1.18% |
| 2020 Q1 | 402.53 Million CNY | -37.68% |
| 2020 Q3 | 513.35 Million CNY | -0.32% |
| 2020 Q4 | 483.85 Million CNY | -5.75% |
| 2020 FY | 1.91 Billion CNY | -6.51% |
| 2020 Q2 | 515.01 Million CNY | 27.94% |
| 2019 Q3 | 547.08 Million CNY | 6.47% |
| 2019 FY | 2.04 Billion CNY | 15.83% |
| 2019 Q1 | 341.3 Million CNY | -35.37% |
| 2019 Q2 | 513.84 Million CNY | 50.55% |
| 2019 Q4 | 645.89 Million CNY | 18.06% |
| 2018 FY | 1.76 Billion CNY | 17.94% |
| 2018 Q4 | 528.11 Million CNY | 17.04% |
| 2018 Q3 | 451.22 Million CNY | -0.39% |
| 2018 Q2 | 452.96 Million CNY | 34.87% |
| 2018 Q1 | 335.86 Million CNY | -36.08% |
| 2017 Q3 | 337.62 Million CNY | 2.47% |
| 2017 FY | 1.49 Billion CNY | -0.87% |
| 2017 Q4 | 525.45 Million CNY | 55.63% |
| 2017 Q1 | 306.68 Million CNY | -41.27% |
| 2017 Q2 | 329.48 Million CNY | 7.43% |
| 2016 Q4 | 522.21 Million CNY | 41.78% |
| 2016 Q3 | 368.33 Million CNY | 2.16% |
| 2016 Q2 | 360.53 Million CNY | 37.94% |
| 2016 FY | 1.51 Billion CNY | 115.0% |
| 2016 Q1 | 261.36 Million CNY | -9.16% |
| 2015 FY | 703.47 Million CNY | 95.51% |
| 2015 Q4 | 287.71 Million CNY | 84.24% |
| 2015 Q3 | 156.16 Million CNY | 33.13% |
| 2015 Q2 | 117.3 Million CNY | -17.56% |
| 2015 Q1 | 142.29 Million CNY | 19.87% |
| 2014 FY | 359.81 Million CNY | 0.18% |
| 2014 Q4 | 118.7 Million CNY | 29.42% |
| 2014 Q3 | 91.72 Million CNY | 20.42% |
| 2014 Q2 | 76.16 Million CNY | 4.02% |
| 2014 Q1 | 73.22 Million CNY | -29.62% |
| 2013 Q1 | 80.07 Million CNY | -9.39% |
| 2013 FY | 359.15 Million CNY | 6.44% |
| 2013 Q3 | 92.78 Million CNY | 12.81% |
| 2013 Q2 | 82.25 Million CNY | 2.72% |
| 2013 Q4 | 104.04 Million CNY | 12.14% |
| 2012 Q3 | 99.49 Million CNY | 0.0% |
| 2012 FY | 337.42 Million CNY | 24.76% |
| 2012 Q4 | 88.37 Million CNY | -11.18% |
| 2011 FY | 270.45 Million CNY | 24.71% |
| 2010 Q4 | 68.49 Million CNY | 0.0% |
| 2010 FY | 216.86 Million CNY | 20.57% |
| 2009 FY | 179.87 Million CNY | 22.16% |
| 2008 FY | 147.24 Million CNY | 71.83% |
| 2007 FY | 85.69 Million CNY | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Chengdu Kanghua Biological Products Co., Ltd. | 1.56 Billion CNY | 49.221% |
| NanHua Bio-medicine Co., Ltd | 136.79 Million CNY | -481.926% |
| Shandong Sito Bio-technology Co., Ltd. | 1.27 Billion CNY | 37.8% |
| Porton Pharma Solutions Ltd. | 3.66 Billion CNY | 78.295% |
| Zhejiang Wecome Pharmaceutical Company Limited | 519.62 Million CNY | -53.193% |